Offianan Andre Toure1, Neena Valecha2, Antoinette K Tshefu3, Ricardo Thompson4, Srivicha Krudsood5, Oumar Gaye6, Bappanaidu Hoigegudde Krishnamurthy Rao7, Issaka Sagara8, Tarit Kumar Bose9, Sanjib Mohanty10, Ballamudi Srinivas Rao11, Anupkumar R Anvikar2, Victor Mwapasa12, Harald Noedl13,14, Sudershan Arora15, Arjun Roy16, Sunil S Iyer17, Pradeep Sharma17, Nilanjan Saha18, Rajinder K Jalali19, Landry Tiacoh, Sonia Enosse, Noppadon Tangpukdee, Jack Kokolomami, Jean-Louis Ndiaye, Deepak Rao, Ntamabyaliro Nsengi Yumva, Bouran Sidibe, Rajesh Mohanty, A C Jha, Mulinda Nyirenda, Peter Starzengruber, Paul Swoboda. 1. Malariology Department, Institut Pasteur Côte d'Ivoire, Abidjan. 2. Epidemiology and Clinical Research Division, National Institute of Malaria Research, New Delhi, India. 3. Centre de recherches cliniques et epidemiologiques de Mont Amba, Centre hospitalier de Mont Amba, Ecole de Sante Publique, Universite de Kinshasa, Democratic Republic of Congo. 4. Chókwè Health Research and Training Centre, Mozambique. 5. Bangkok Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Thailand. 6. Department of Parasitology Guediawaye District Hospital, University Cheikh Anta Diop, Dakar Fann, Senegal. 7. Department of Medicine, Government Wenlock District Hospital, Mangalore, Karnataka, India. 8. Malaria Research and Training Center, University of Science, Techniques and Technologies Bamako, Mali. 9. Community Welfare Society Hospital, Jagda. 10. Ispat General Hospital, Rourkela, Odisha. 11. Department of Medicine, Tata Main Hospital, Jamshedpur, Jharkhand, India. 12. College of Medicine, Blantyre, Malawi. 13. Malaria Research Initiative Bandarban, Sadar District Hospital, Bangladesh. 14. Institute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Austria. 15. Corporate Office. 16. CDM & Biostatistics, Medical Affairs & Clinical Research. 17. Clinical Pharmacology & Pharmacokinetics. 18. Medical Global Marketing, Corporate Office. 19. Medical Affairs & Clinical Research, Sun Pharmaceutical Industries Limited (erstwhile Ranbaxy Laboratories Ltd), Gurgaon, Haryana, India.
Abstract
BACKGROUND: Artemisinins, which are derived from plants, are subject to risk of supply interruption due to climatic changes. Consequently, an effort to identify a new synthetic antimalarial was initiated. A fixed-dose combination of arterolane maleate (AM), a new synthetic trioxolane, with piperaquine phosphate (PQP), a long half-life bisquinoline, was evaluated in patients with uncomplicatedPlasmodium falciparummalaria. METHODS: In this multicenter, randomized, double-blind, comparative, parallel-group trial, 1072 patients aged 12-65 years withP. falciparummonoinfection received eitherAM-PQP (714 patients) once daily or artemether-lumefantrine (A-L; 358 patients) twice daily for 3 days. All patients were followed up until day 42. RESULTS: Of the 714 patients in the AM-PQP group, 638 (89.4%) completed the study; of the 358 patients in the A-L group, 301(84.1%) completed the study. In both groups, the polymerase chain reaction corrected adequate clinical and parasitological response (PCR-corrected ACPR) on day 28 in intent-to-treat (ITT) and per-protocol (PP) populations was 92.86% and 92.46% and 99.25% and 99.07%, respectively. The corresponding figures on day 42 in the ITT and PP populations were 90.48% and 91.34%, respectively. After adjusting for survival ITT, the PCR-corrected ACPR on day 42 was >98% in both groups. The overall incidence of adverse events was comparable. CONCLUSIONS: AM-PQP showed comparable efficacy and safety to A-L in the treatment of uncomplicatedP. falciparummalaria in adolescent and adult patients. AM-PQP demonstrated high clinical and parasitological response rates as well as rapid parasite clearance. CLINICAL TRIALS REGISTRATION: India. CTRI/2009/091/000101.
RCT Entities:
BACKGROUND:Artemisinins, which are derived from plants, are subject to risk of supply interruption due to climatic changes. Consequently, an effort to identify a new synthetic antimalarial was initiated. A fixed-dose combination of arterolane maleate (AM), a new synthetic trioxolane, with piperaquine phosphate (PQP), a long half-life bisquinoline, was evaluated in patients with uncomplicatedPlasmodium falciparummalaria. METHODS: In this multicenter, randomized, double-blind, comparative, parallel-group trial, 1072 patients aged 12-65 years withP. falciparummonoinfection received either AM-PQP (714 patients) once daily or artemether-lumefantrine (A-L; 358 patients) twice daily for 3 days. All patients were followed up until day 42. RESULTS: Of the 714 patients in the AM-PQP group, 638 (89.4%) completed the study; of the 358 patients in the A-L group, 301(84.1%) completed the study. In both groups, the polymerase chain reaction corrected adequate clinical and parasitological response (PCR-corrected ACPR) on day 28 in intent-to-treat (ITT) and per-protocol (PP) populations was 92.86% and 92.46% and 99.25% and 99.07%, respectively. The corresponding figures on day 42 in the ITT and PP populations were 90.48% and 91.34%, respectively. After adjusting for survival ITT, the PCR-corrected ACPR on day 42 was >98% in both groups. The overall incidence of adverse events was comparable. CONCLUSIONS:AM-PQP showed comparable efficacy and safety to A-L in the treatment of uncomplicatedP. falciparummalaria in adolescent and adult patients. AM-PQP demonstrated high clinical and parasitological response rates as well as rapid parasite clearance. CLINICAL TRIALS REGISTRATION: India. CTRI/2009/091/000101.
Authors: Oliver T Mytton; Elizabeth A Ashley; Leon Peto; Ric N Price; Yar La; Rae Hae; Pratap Singhasivanon; Nicholas J White; François Nosten Journal: Am J Trop Med Hyg Date: 2007-09 Impact factor: 2.345
Authors: Neena Valecha; Srivicha Krudsood; Noppadon Tangpukdee; Sanjib Mohanty; S K Sharma; P K Tyagi; Anupkumar Anvikar; Rajesh Mohanty; B S Rao; A C Jha; B Shahi; Jai Prakash Narayan Singh; Arjun Roy; Pawandeep Kaur; Monica Kothari; Shantanu Mehta; Anirudh Gautam; Jyoti K Paliwal; Sudershan Arora; Nilanjan Saha Journal: Clin Infect Dis Date: 2012-05-14 Impact factor: 9.079
Authors: R N Price; A R Hasugian; A Ratcliff; H Siswantoro; H L E Purba; E Kenangalem; N Lindegardh; P Penttinen; F Laihad; E P Ebsworth; N M Anstey; E Tjitra Journal: Antimicrob Agents Chemother Date: 2007-09-10 Impact factor: 5.191
Authors: Julien Zwang; Elizabeth A Ashley; Corine Karema; Umberto D'Alessandro; Frank Smithuis; Grant Dorsey; Bart Janssens; Mayfong Mayxay; Paul Newton; Pratap Singhasivanon; Kasia Stepniewska; Nicholas J White; François Nosten Journal: PLoS One Date: 2009-07-29 Impact factor: 3.240
Authors: Xin Hui S Chan; Yan Naung Win; Ilsa L Haeusler; Jireh Y Tan; Shanghavie Loganathan; Sompob Saralamba; Shu Kiat S Chan; Elizabeth A Ashley; Karen I Barnes; Rita Baiden; Peter U Bassi; Abdoulaye Djimde; Grant Dorsey; Stephan Duparc; Borimas Hanboonkunupakarn; Feiko O Ter Kuile; Marcus V G Lacerda; Amit Nasa; François H Nosten; Cyprian O Onyeji; Sasithon Pukrittayakamee; André M Siqueira; Joel Tarning; Walter R J Taylor; Giovanni Valentini; Michèle van Vugt; David Wesche; Nicholas P J Day; Christopher L-H Huang; Josep Brugada; Ric N Price; Nicholas J White Journal: PLoS Med Date: 2020-03-05 Impact factor: 11.069
Authors: Mainga Hamaluba; Rob W van der Pluijm; Joseph Weya; Patricia Njuguna; Mwanajuma Ngama; Peter Kalume; Gabriel Mwambingu; Caroline Ngetsa; Juliana Wambua; Mwanamvua Boga; Neema Mturi; Altaf A Lal; Arshad Khuroo; Walter R J Taylor; Sónia Gonçalves; Olivo Miotto; Mehul Dhorda; Brian Mutinda; Mavuto Mukaka; Naomi Waithira; Richard M Hoglund; Mallika Imwong; Joel Tarning; Nicholas P J Day; Nicholas J White; Philip Bejon; Arjen M Dondorp Journal: Lancet Infect Dis Date: 2021-06-07 Impact factor: 71.421